Cargando…

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor

Understanding the HIV integrase protein and mechanisms of resistance to HIV integrase inhibitors is complicated by the lack of a full length HIV integrase crystal structure. Moreover, a lentiviral integrase structure with co-crystallised DNA has not been described. For these reasons, we have develop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quashie, Peter K., Han, Ying-Shan, Hassounah, Said, Mesplède, Thibault, Wainberg, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4457863/ https://www.ncbi.nlm.nih.gov/pubmed/26046987 http://dx.doi.org/10.1371/journal.pone.0128310

Ejemplares similares

Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review
por: Hassounah, Said A., et al.
Publicado: (2016)

Integrase Strand Transfer Inhibitors in HIV Therapy
por: Mesplède, Thibault, et al.
Publicado: (2013)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
por: Mesplède, Thibault, et al.
Publicado: (2015)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M
por: Depatureaux, Agnès, et al.
Publicado: (2014)

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
por: Wares, Melissa, et al.
Publicado: (2014)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

Novel therapeutic strategies targeting HIV integrase
por: Quashie, Peter K, et al.
Publicado: (2012)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
por: Raffi, Francois, et al.
Publicado: (2012)

Will LEDGIN molecules be able to play a role in a cure for HIV infection?
por: Mesplède, Thibault, et al.
Publicado: (2016)

Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity
por: Singhroy, Diane N, et al.
Publicado: (2013)

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy
por: Wainberg, Mark A, et al.
Publicado: (2015)

What if HIV were unable to develop resistance against a new therapeutic agent?
por: Wainberg, Mark A, et al.
Publicado: (2013)

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses
por: Pham, Hanh T., et al.
Publicado: (2016)

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance
por: Wainberg, Mark A.
Publicado: (2012)

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
por: Mesplède, Thibault, et al.
Publicado: (2013)

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
por: Mesplède, Thibault, et al.
Publicado: (2014)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Pre-organized structure of viral DNA at the binding-processing site of HIV-1 integrase
por: Renisio, Jean-Guillaume, et al.
Publicado: (2005)

Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany
por: Meixenberger, Karolin, et al.
Publicado: (2014)

Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency
por: Bastarache, Sophie M., et al.
Publicado: (2014)

Novel 3′-Processing Integrase Activity Assay by Real-Time PCR for Screening and Identification of HIV-1 Integrase Inhibitors
por: Sakkhachornphop, Supachai, et al.
Publicado: (2015)

Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis
por: Hutapea, Hotma Martogi Lorensi, et al.
Publicado: (2018)

Design of inhibitors of the HIV-1 integrase core domain using virtual screening
por: Regon, Preetom, et al.
Publicado: (2014)

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration
por: Mesplède, Thibault, et al.
Publicado: (2017)

Binding mode prediction of biologically active compounds from plant Salvia Miltiorrhiza as integrase inhibitor
por: Nunthaboot, Nadtanet, et al.
Publicado: (2013)

HIV-2 Integrase Variation in Integrase Inhibitor-Naïve Adults in Senegal, West Africa
por: Gottlieb, Geoffrey S., et al.
Publicado: (2011)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
por: Koneru, Pratibha C, et al.
Publicado: (2019)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Patterns of resistance development with integrase inhibitors in HIV
por: Mbisa, Jean L, et al.
Publicado: (2011)

Update on Adverse Effects of HIV Integrase Inhibitors
por: Kolakowska, Agnieszka, et al.
Publicado: (2019)

Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study
por: Palanisamy, Navaneethan, et al.
Publicado: (2017)

Erratum for Mesplède et al., “The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration”
por: Mesplède, Thibault, et al.
Publicado: (2018)

HIV-1 Integrase-DNA Recognition Mechanisms
por: Kessl, Jacques J., et al.
Publicado: (2009)

Characterization of the HIV-1 integrase chromatin- and LEDGF/p75-binding abilities by mutagenic analysis within the catalytic core domain of integrase
por: Zheng, Yingfeng, et al.
Publicado: (2010)

Characterization of HIV-1 Integrase Gene and Resistance Associated Mutations Prior to Roll out of Integrase Inhibitors by Kenyan National HIV-Treatment Program in Kenya
por: Mabeya, Sepha, et al.
Publicado: (2020)

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases
por: Zhao, Xue Zhi, et al.
Publicado: (2016)

HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants
por: Smith, Steven J., et al.
Publicado: (2021)

Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes
por: Bar-Magen, Tamara, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_2icmkquvqpteso7mhlqv9sppek